Mirum Pharmaceuticals, Inc. Operating Expenses
Mirum Pharmaceuticals, Inc. (MIRM) reported Operating Expenses of $218.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $218.78M, a 64.78% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $949.35M, a 648.89% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $153.50M, a 24.15% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $130.41M, a 26.53% increase year-over-year.
- Mirum Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $543.45M, a 28.02% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $424.49M, a 43.64% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $295.53M, a 41.89% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $208.28M, a 8.17% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 5 month | Operating Expenses 6 month | Operating Expenses 8 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $218.78M 10-Q · filed 2026-08-05 | $1.17B 10-Q · filed 2026-08-05 | $1.32B derived: sum of 3 quarters · filed 2026-08-05 | $1.45B derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $949.35M 10-Q · filed 2026-05-06 | $1.10B derived: sum of 2 quarters · filed 2026-05-06 | $1.23B derived: sum of 3 quarters · filed 2026-05-06 | $1.37B derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $153.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $283.91M derived: sum of 2 quarters · filed 2026-02-25 | $416.68M derived: sum of 3 quarters · filed 2026-08-05 | $543.45M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | $130.41M 10-Q · filed 2025-11-04 | $263.18M derived: sum of 2 quarters · filed 2026-08-05 | $389.95M 10-Q · filed 2025-11-04 | $513.59M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $132.77M 10-Q · filed 2026-08-05 | $259.54M 10-Q · filed 2026-08-05 | $383.18M derived: sum of 3 quarters · filed 2026-08-05 | $486.24M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $126.77M 10-Q · filed 2026-05-06 | $250.40M derived: sum of 2 quarters · filed 2026-05-06 | $353.46M derived: sum of 3 quarters · filed 2026-05-06 | $455.57M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $123.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $226.70M derived: sum of 2 quarters · filed 2026-02-25 | $328.80M derived: sum of 3 quarters · filed 2026-02-25 | $424.49M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | $103.06M 10-Q · filed 2025-11-04 | $205.17M derived: sum of 2 quarters · filed 2025-11-04 | $300.86M 10-Q · filed 2025-11-04 | $403.00M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | $102.11M 10-Q · filed 2025-08-06 | $197.80M 10-Q · filed 2025-08-06 | $299.94M derived: sum of 3 quarters · filed 2026-02-25 | $372.81M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | $95.69M 10-Q · filed 2025-05-07 | $197.83M derived: sum of 2 quarters · filed 2026-02-25 | $270.70M derived: sum of 3 quarters · filed 2026-02-25 | $332.47M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | $102.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $175.01M derived: sum of 2 quarters · filed 2026-02-25 | $236.78M derived: sum of 3 quarters · filed 2026-02-25 | $295.53M 10-K · filed 2026-02-25 | ||
| 2023-09-30 | $72.87M 10-Q · filed 2024-11-12 | $134.64M derived: sum of 2 quarters · filed 2024-11-12 | $193.39M 10-Q · filed 2024-11-12 | $255.46M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $61.77M 10-Q · filed 2024-08-07 | $120.52M 10-Q · filed 2024-08-07 | $182.58M derived: sum of 3 quarters · filed 2025-02-26 | $234.25M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $58.75M 10-Q · filed 2024-05-08 | $120.81M derived: sum of 2 quarters · filed 2025-02-26 | $172.47M derived: sum of 3 quarters · filed 2025-02-26 | $221.40M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $62.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $113.73M derived: sum of 2 quarters · filed 2025-02-26 | $162.65M derived: sum of 3 quarters · filed 2025-02-26 | $208.28M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $51.66M 10-Q · filed 2023-11-02 | $100.59M derived: sum of 2 quarters · filed 2023-11-02 | $146.22M 10-Q · filed 2023-11-02 | $194.93M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-06-30 | $48.92M 10-Q · filed 2023-08-07 | $94.55M 10-Q · filed 2023-08-07 | $143.27M derived: sum of 3 quarters · filed 2024-03-15 | $191.09M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-03-31 | $45.63M 10-Q · filed 2023-05-04 | $94.34M derived: sum of 2 quarters · filed 2024-03-15 | $142.16M derived: sum of 3 quarters · filed 2024-03-15 | $190.57M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2021-12-31 | $48.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $96.54M derived: sum of 2 quarters · filed 2024-03-15 | $144.94M derived: sum of 3 quarters · filed 2024-03-15 | $192.55M 10-K · filed 2024-03-15 | ||
| 2021-09-30 | $47.82M 10-Q · filed 2022-11-09 | $96.22M derived: sum of 2 quarters · filed 2022-11-09 | $143.84M 10-Q · filed 2022-11-09 | $180.79M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $48.40M 10-Q · filed 2022-08-04 | $96.01M 10-Q · filed 2022-08-04 | $132.97M derived: sum of 3 quarters · filed 2022-08-04 | $154.68M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $47.61M 10-Q · filed 2022-05-05 | $84.56M derived: sum of 2 quarters · filed 2022-05-05 | $106.28M derived: sum of 3 quarters · filed 2022-05-05 | $129.88M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $36.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $58.67M derived: sum of 2 quarters · filed 2022-03-09 | $82.26M derived: sum of 3 quarters · filed 2022-03-09 | $104.30M 10-K · filed 2022-03-09 | ||
| 2020-09-30 | $21.72M 10-Q · filed 2021-11-15 | $45.31M derived: sum of 2 quarters · filed 2021-11-15 | $67.34M 10-Q · filed 2021-11-15 | $86.00M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $23.60M 10-Q · filed 2021-08-05 | $45.63M 10-Q · filed 2021-08-05 | $64.29M derived: sum of 3 quarters · filed 2021-08-05 | $80.15M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $22.03M 10-Q · filed 2021-05-06 | $40.69M derived: sum of 2 quarters · filed 2021-05-06 | $56.56M derived: sum of 3 quarters · filed 2021-05-06 | $70.59M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $18.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $34.52M derived: sum of 2 quarters · filed 2021-03-09 | $48.56M derived: sum of 3 quarters · filed 2021-03-09 | $54.74M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | $15.87M 10-Q · filed 2020-11-12 | $29.90M derived: sum of 2 quarters · filed 2020-11-12 | $36.09M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $14.03M 10-Q · filed 2020-08-06 | $20.22M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | $6.18M 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | $17.41M 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | $65.00K 10-Q · filed 2019-11-06 | $75.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |